GLAXF News and Press, GlaxoSmithKline Plc From 11/13/21

DWX is an international dividend ETF. It is overweight in Europe, utilities and financials. Total return since inception is underwhelming relative to competitors. Why I prefer DNL. For further details see: DWX: Past Performance Is Concerning

IDV strategy and portfolio. Past performance vs. competitors. Takeaway. For further details see: IDV: An International High Yield ETF Heavy In Financials

SCHY strategy and portfolio. Past performance vs. competitors. Takeaway. For further details see: SCHY: International Dividend ETF Mitigating Risks

Gilead Sciences and Gritstone bio have a collaboration on a vaccine platform for curing HIV. Gilead has already paid $30 million upfront and bought $35 million in stock. Gritstone bio recently completed a $55 million PIPE with leading life sciences investors Frazier Life Sciences, Red...

VYMI strategy and portfolio. Past performance vs. competitors. Takeaway. For further details see: VYMI: International High Yield Overweight In Financials

Kahn Brothers’ 13F portfolio value increased from $698M to $710M this quarter. Pfizer, VOXX International, and ViewRay were increased substantially during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F...

Fisher’s 13F portfolio value increased from ~$159B to ~$161B in Q3 2021. Advanced Micro Devices, Facebook, and Lam Research were increased while reducing Visa this quarter. The top three positions are Apple, Microsoft, and Amazon. They add up to ~14% of the portfolio. ...

GlaxoSmithKline plc (GSK) Q3 2021 Earnings Conference Call October 27, 2021, 09:00 AM ET Company Participants Emma Walmsley – CEO Nick Stone – Head of Investor Relations Brian McNamara – CEO of GSK Consumer Healthcare Iain Mackay – CFO Hal Barron – Chief Sci...

GlaxoSmithKline plc (GSK) Citi's 16th Annual BioPharma Virtual Conference September 09, 2021 01:25 PM ET Company Participants Kimberly Smith - Head of R&D, ViiV Conference Call Participants Andrew Baum - Citi Presentation Andrew Baum Good afternoon. Delighted that you could join the GSK w...

Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...